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A multi-center retrospective review of major prosthetic graft infection outcomes was under-
taken to determine graft preservation and limb salvage rates. The management of infected
prosthetic vascular grafts continues to be controversial. The purpose of this study was to re-
view the surgical management of major extracavitary prosthetic vascular graft infections
and to correlate the outcomes on the basis of bacteriology and grade. The change in patient
population seen by vascular surgeons and the recent emergence of more virulent bacterial
strains should influence surgical management. Bacteriology and severity of infection based
on grade must play a greater role in the selection criteria for graft salvage. Despite advance-
ment in the understanding of these interactions and the emergence of new management al-
gorithms, we are continuing to operate without a uniform standard in managing this difficult
and rapidly evolving clinical problem.
INTRODUCTION
The incidence of prosthetic graft infec-
tions has been reported to vary from 1 per-
cent to 6 percent [1-5]. Several series have
demonstrated an overall improvement in
the morbidity and mortality of operative
treatment of infected vascular prostheses
[1,6-8]. Successful management can be at-
tributed to the development of better stag-
ing systems, operative delineation of the
extent of infection, and a better apprecia-
tion of the potential virulence of the mi-
crobes involved [3,8,9].
Samson [10], as well as Koenig and
vonDongen [11], have modified the widely
used classification system of extracavitary
vascular graft infections established by Szi-
lagyi [12]. These modifications allow for
more precise prognostication and directed
treatment (Table 1).
Debate continues over the indications
for graft salvage vs. excision in extracavi-
tary prosthetic graft infections. Tradition-
ally, graft infections were treated by
removal, over sewing of the vessel, with
extra-anatomic bypass.While this modality
continues to have its proponents [2,13-15],
the significant morbidity of this procedure
has been well documented [15,16]. Graft
salvage and route salvage techniques have
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bed anatomy. Long-term success has been
attainable in many case series with aggres-
sive operative debridement and rotational
muscle flaps [1,2,4-6,16-24].
This study was prompted by a combi-
nation of the recent changes in the profile of
patients treated by vascular surgeons, alter-
ations in microbiologic isolates, and an at-
tempt to assess the variability of practice
patterns in light of current clinical guide-
lines.
A multi-center retrospective study was
conducted to determine the primary mode of
therapy and rate of limb salvage for major
prosthetic graft infections. Only Samson
groups 3 through 5 extracavitary and distal
limb aortofemoral grafts were reviewed.
Groups 1 and 2 were excluded, as these in-
fections do not involve the graft itself. This
study attempted to correlate grade, bacteriol-
ogy, and outcomes and compare these based
on choice of surgical intervention. This is
the first study in the literature to do so.
PATIENTS AND METHODS
A retrospective review of records was
completed at three hospitals: the University
of California-Irvine Medical Center, Yale
New Haven Medical Center, and an affiliate,
the Hospital of Saint Raphael. We obtained
permission to perform this study from the in-
stitutional review boards of all three hospi-
tals. The data were obtained through an
extensive review of all medical records and
outpatient clinic charts of vascular bypasses
performed from 1997 to 2002. Only extra-
cavitary graft infections and distal segments
of aortofemoral prosthetic grafts were in-
cluded in the study population. Isolated in-
tracavitary and arteriovenous prosthetic
grafts were excluded. The Samson modifi-
cation of the Szilagyi system was used to se-
lect only patients with group 3 through 5
infections (as noted by clinical and operative
notes). Data were collected on the initial op-
eration and its indication, the type of pros-
thesis, the timing of infection, bacteriology,
treatment, and outcome. Follow-up was con-
cluded at the death of the subject or at the
end of data collection in May 2004.
Statisticalanalyseswereperformedwith
SPSS for Windows (SPSS 12.0; SPSS Inc.,
Chicago, IL). Both descriptive and inferen-
tial statistical methods were used.All testing
was based on determining statistical signifi-
cance at a two-sided P level of .05. We used
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Szilagyi [12] classification
Group 1
Group 2
Group 3
Definition
Infection involves only the
dermis
Infection extends into the
subcutaneous tissue but
does not invade the arte-
rial implant
The arterial implant
proper is involved in the
infection
Samson [10] classification
Group 1
Group 2
Group 3
Group 4
Group 5
Definition
Infections extend no
deeper than the dermis
Infections involve subcu-
taneous tissues but do not
come into grossly observ-
able direct contact with
the graft
Infections involve the
body of the graft but not at
an anastomosis
Infections surround an ex-
posed anastomosis, but
bacteremia or anasto-
motic bleeding has not oc-
curred
Infections involve a graft-
to-artery anastomosis and
are associated with sep-
ticemia and/or bleeding at
the time of presentation
Table 1. Prosthetic Graft Infection ClassificationsFisher’s exact tests to compare categorical
variables with other categorical variables.
RESULTS
Forty-five subjects (23 men and 22
women) met the criteria for inclusion in this
study. Subjects ranged in age from 40 to 85
years (mean, 67 years). Follow-up time
ranged from 2 to 72 months, with an average
of 27 months.
The revascularization procedures per-
formed before the onset of infection are
listed in Table 2. The most common indica-
tions for operation were tissue loss (n = 20;
44 percent) and claudication (n = 15; 33 per-
cent). The indication for the remaining 23
percent could not be assigned from the med-
ical record but were either tissue loss or
claudication. The infected grafts were poly-
tetrafluoroethylene in 34 cases, Dacron
(DuPont, Wilmington, Delaware) in eight
cases, and composite grafts in three cases.
The time from implantation to the develop-
ment of infection was documented as either
early (less than 4 months; n = 30; 64 per-
cent) or late (greater than 4 months; n = 15;
36 percent). Data for Samson groups 3
through 5 are shown in Table 3.
Aerobic, anaerobic, and fungal cultures
were obtained with swabs from all grafts
during the operation.The groin was the most
common site of infection (n = 37; 82 per-
cent).The most common organisms cultured
are listed in Table 3.
Bacteriology was available in 38 of 45
cases. Gram-negative organisms were cul-
tured in abundance in this series: 16 (45 per-
cent) cases harbored Gram-negative
organisms, and of those, only three were
Pseudomonas aeruginosa. Two of three
(group 3) patients with P. aeruginosa infec-
tions experienced limb salvage failure with
either muscle flap or ex situ bypass. Six (55
percent) of 11 amputations occurred in pa-
tients with Gram-negative infections, and
two (67 percent) of three perioperative
deaths were related to Gram-negative sepsis.
Staphylococcus epidermidis was the most
common Gram-positive organism cultured
(32 percent), followed by methicillin-resis-
tant Staphylococcus aureus (MRSA) (26
percent). Muscle flaps or in situ bypass re-
placements were used to treat 71 percent of
group 3 S. epidermidis-infected grafts.
Group 4 and 5 S. epidermidis cases were
treated primarily by excision.
The treatment regimens for MRSA-in-
fected grafts were as mixed as the results
(Table 4): 50 percent of MRSA-infected
grafts were excised, 30 percent were sal-
vaged, and 20 percent were treated by in situ
graft replacement and muscle flap transposi-
tion. There was a 42.9 percent amputation
rate and a 57.1 percent limb salvage rate for
MRSA-infected group 3 cases.
The primary mode of therapy was mus-
cle flap transposition, alone (n = 15) or with
in situ graft replacement (n = 3). A total of
18 (40 percent) muscle flaps were per-
formed. Ten (67 percent) of 15 grafts were
preserved with muscle flap transposition.
Although there was no statistical signifi-
cance (P = .081), muscle flaps were used
more often for group 3 compared with
groups 4 and 5, whereas irrigation and de-
bridement were used more frequently for
group 4. Ex situ and in situ graft replace-
ments were used more often for group 5
cases (Table 5).
Samson group 3 (n = 30) cases were
treated mostly by graft excision (n = 16; 53
percent), and fewer than half were preserved
(n = 14; 46 percent). The Samson group 4 (n
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Table 2. Type of Vascular Bypass
Vascular Bypass N
Aortofemoral 7
Femoropopliteal 12
Femorodistal 8
Femorofemoral 10
Axillofemoral 4
Femoro-interpositional 4
Total 45116 Narayan: Prosthetic vascular graft infection
Table 3. Organism and Treatment Data
Patient No. Group* Organism Treatment Outcome
13Citrobacter koseri Flap Limb salvage
23 Diphtheroids, Escherichia coli Flap Amputation
33 Enterobacter sp. Excision Limb salvage
43 Enterobacter sp., enterococci Flap Amputation
53 GNR Excision Amputation
63 MRSA Ex situ Amputation
73 MRSA Excision Limb salvage
83 MRSA Excision Limb salvage
93 MRSA I & D Limb salvage
10 3 MRSA I & D Limb salvage
11 3 MRSA In situ & flap Amputation
12 3 MRSA, Pseudomonas sp. Excision Amputation
13 3 No growth Excision Death
14 3 No growth Excision Limb salvage
15 3 No growth Flap Limb salvage
16 3 No growth I & D Limb salvage
17 3 No growth I & D Limb salvage
18 3 Proteus sp., E. coli, Enterobacter sp. Flap Limb salvage
19 3 Pseudomonas sp. Flap Amputation
20 3 Pseudomonas sp., enterococci Ex situ Amputation
21 3 Staphylococcus aureus Flap Amputation
22 3 S. aureus, diphtheroids In situ Amputation
23 3 S. epidermidis Excision Limb salvage
24 3 S. epidermidis Flap Limb salvage
25 3 S. epidermidis Flap Limb salvage
26 3 S. epidermidis Flap Limb salvage
27 3 S. epidermidis In situ Limb salvage
28 3 S. epidermidis, Bacteroides sp. Flap Limb salvage
29 3 S. epidermidis, Torulopsis glabrata Excision Limb salvage
30 3 Streptococci, diphtheroids, Proteus sp Flap Limb salvage
31 4 Citrobacter sp. I & D Limb salvage
32 4 Enterobacter and Candida sp. Ex situ Limb salvage
33 4 MRSA; Enterobacter and Candida sp. Flap Limb salvage
34 4 MRSA, S. epidermidis, diphtheroids Ex situ Limb salvage
35 4 No growth I & D Limb salvage
36 4 Proteus sp., E. coli, Morganella sp. I & D Death
37 4 Proteus sp., Haemophilus influenzae Flap Limb salvage
38 4 S. epidermidis Excision Limb salvage
39 4 S. epidermidis, enterococci Excision Limb salvage
40 5 MRSA In situ & flap Limb salvage
41 5 No growth Flap Amputation
42 5 S. aureus Excision Limb salvage
43 5 S. aureus, diphtheroids,
Enterobacter sp., yeast Ex situ Death
44 5 S. epidermidis, Bacteroides sp. In situ & flap Limb salvage
45 5 S. epidermidis, Candida sp. Ex situ Limb salvage
*Samson classification.
GNR, gram-negative rod; MRSA, methicillin-resistant Staphylococcus aureus; I & D, irrigation and debridement.= 9) and group 5 (n = 6) cases were managed
with a variety of surgical treatments: ex situ
bypass (n = 4; 27 percent), graft excision
alone(n=3;20percent),muscleflaps(n=3;
20 percent), and in situ bypass with muscle
flap (n = 2; 13 percent) (Table 3). Addition-
ally, irrigation and debridement according to
KwaanandConnolly’smethod[21]wasper-
formed on three patients (20 percent).
Three perioperative deaths were related
to graft infection; the other eight deaths were
from various unrelated causes. Overall, there
was a 6 percent perioperative mortality rate
in this series. There were 11 total amputa-
tions (24 percent).
Table 6 shows the distribution of out-
comes by group and organism.The distribu-
tion of outcomes was statistically significant
between organism type for group 3 (P = .03)
but not for groups 4 (P = .9) or 5 (P = .3).
Group 3 patients with Gram-negative or
MRSA-infected grafts were less likely to
achieve limb salvage than those infected
with S. epidermidis or negative cultures. Be-
yond this, there was insufficient evidence to
suggest outcomes varied by group, organ-
ism, or treatment method.
DISCUSSION
This study is the first of its kind to eval-
uate management practices of extracavitary
prosthetic vascular graft infections based on
the extent of infection by Samson grading
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Table 4. Distribution of Treatment Modalities by Organisms
Surgical Treatment
Organism Ex Situ Excision Flap I&D In Situ In Situ Total
and Flap
MRSA 2 (20.0%) 3 (30.0%) 1 (10.0%) 2 (20.0%) 0 2 (20.0%) 10 (100.0%)
S. epidermidis 1 (9.1%) 4 (36.4%) 4 (36.4%) 0 1 (9.1%) 1 (9.1%) 11 (100.0%)
Gram-negative
organisms 3 (21.4%) 2 (14.3%) 7 (50.0%) 2 (14.3%) 00 14 (100.0%)
No growth 0 2 (28.6%) 2 (28.6%) 3 (42.9%) 00 7 (100.0%)
Total 6 11 14 7 1 3 42
(14.3%) (26.2%) (33.3%) (16.7%) (2.4%) (7.1%) (100.0%)
Data are count (% within organism).
I & D, irrigation and debridement; MRSA, methicillin-resistant Staphylococcus aureus.
Table 5. Distribution of Treatment Modalities by Group
Surgical Treatment
Group Ex Situ Excision Flap I&D In Situ In Situ Total
and Flap
3 2 (7.1%) 9 (32.1%) 11 (39.3%) 4 (14.3%) 1 (3.6%) 1 (3.6%) 28 (100.0%)
4 2 (22.2%) 2 (22.2%) 2 (22.2%) 3 (33.3%) 0 0 9 (100.0%)
5 2 (40.0%) 0 1 (20.0%) 0 0 2 (40.0%) 5 (100.0%)
Total 6 11 14 7 1 3 42
(14.3%) (26.2%) (33.3%) (16.7%) (2.4%) (7.1%) (100.0%)
Data are count (% within group).
I & D, irrigation and debridement.and bacteriology. It is clear from this analy-
sis that surgeons have not yet broadly
adopted these management principles and
continue to select widely divergent interven-
tions for a given infection.
Success of graft or route salvage is
often determined by the infective organism,
with pseudomonas- and MRSA-infected
grafts being particularly difficult to salvage
[7,25]. Generally, the microbiologic profile
of prosthetic vascular graft infections mir-
rors that of nosocomial infections, and there
is great concern that patterns of sensitivity
are rapidly and continuously changing
[26,27]. Graft and route salvage have been
met with success in other series, particularly
when infected with S. epidermidis, as well
as some Gram-positive and Gram-negative
organisms [2,7,8,5]. Despite this evidence in
the literature, the data found in Table 3 and
Table 4 indicate bacteriology did not play a
consistent role in the management algo-
rithms of these institutions.
The current literature indicates Samson
group 3 patients are most often considered
for graft salvage and route salvage (in situ
reconstruction) [28]. Aggressive perigraft
debridement with vascularized muscle trans-
position has been a very successful treat-
ment method for group 3 infections (Table
7). We were surprised to find the Samson
group 3 (n = 30) cases were treated mostly
by graft excision (n = 16; 53 percent) instead
of preservation (n = 14; 46 percent). Those
Samson group 3 patients who were treated
with muscle flap and graft salvage in this
study resulted in seven of 11 limbs salvaged,
results comparable to those in other studies
(Table 7).
Table 3 illustrates that patients in Sam-
son group 4 were managed in an ad hoc
manner, and there was no sign that bacteri-
ology influenced treatment choice. Our data
indicate bacteriology played a key role in
determining the outcome for group 3 cases,
but not for group 4 or 5 cases, perhaps be-
cause of the small sample size. Unfortu-
nately, therapeutic decisions were not
guided by bacteriology. This may have di-
minished overall graft preservation and limb
salvage rates.
The prevalence of methicillin-resistant
Staphylococcus aureus in the vascular sur-
gery patient has increased since the sample
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Table 6. Distribution of Outcomes by Group and Organism
Outcome
Organism
Group 3
MRSA
Staphylococcus epidermidis
Gram-negative
No growth
Total
Group 4
MRSA
S. epidermidis
Gram-negative
No growth
Total
Group 5
MRSA
S. epidermidis
Gram-negative
No growth
Total
Data are count (% within organism).
MRSA, methicillin-resistant Staphylococcus aureus.
Amputation
3 (42.9%)
0
5 (55.6%)
0
8 (28.6%)
0
0
0
1 (100.0%)
1 (20.0%)
Death
0
0
0
1 (20.0%)
1 (3.6%)
0
0
1 (25.0%)
0
1 (11.1%)
0
0
1 (100.0%)
0
1 (20.0%)
Limb salvage
4 (57.1%)
7 (100.0%)
4 (44.4%)
4 (80.0%)
19 (67.9%)
2 (100.0%)
2 (100.0%)
3 (75.0%)
1 (100.0%)
8 (88.9%)
1 (100.0%)
2 (100.0%)
0
0
3 (60.0%)
Total
7 (100.0%)
7 (100.0%)
9 (100.0%)
5 (100.0%)
28 (100.0%)
2 (100.0%)
2 (100.0%)
4 (100.0%)
1 (100.0%)
9 (100.0%)
1 (100.0%)
2 (100.0%)
1 (100.0%)
1 (100.0%)
5 (100.0%)of patients in this study was taken. Wide-
spread misuse of antibiotics and a lack of
compliance with preventative measures in
the hospital setting have been credited for a
rapid increase in prevalence of MRSAinfec-
tion [29]. A recent study cited MRSA as
being the leading cause of post-operative in-
fection in vascular surgery patients [30].
The current literature suggests that
MRSA-infected graft preservation should
only be attempted with minor graft involve-
ment [25,31]. The high proportion of ampu-
tations (24 percent) was likely due to the
prevalence of MRSAand the excision of the
graft in a population with already threatened
limbs. Despite the success of irrigation and
debridement in group 3 MRSA-infected
grafts in our sample, it is probably impru-
dent to treat this virulent organism with local
measures alone.
Poor outcomes with pseudomonas in-
fections in this study were expected based
on the literature from Calligaro, et al. [7]
Our results suggest that pseudomonas infec-
tions of grade 3 or higher are best treated
with excision.
The incidence of S. epidermidis was
likely underestimated, particularly in the no-
growth cultures, because of the routine
swabbing of wound cultures [32]. Other mi-
crobiologic methods, such as ultrasonifica-
tion, are essential to increase the detection
of S. epidermidis [3]. The low virulence of
this organism makes either muscle flap sal-
vage or in situ graft replacement a reason-
able option [2,7,8,15]. Our limb salvage rate
for S. epidermidis infections was 100 per-
cent; however, only 4 (36 percent) of 11
grafts were preserved with muscle flaps.
Many limbs were salvaged (six of
seven; 86 percent) with irrigation and de-
bridement alone. This method can be used
with success in critically ill patients; how-
ever, the use of a muscle flap would greatly
decrease the risks associated with this
process. These risks include graft desicca-
tion, thrombosis, rupture, and prolonged
hospital stays [21].The use of irrigation and
debridement as the sole therapy in group 4
Gram-negative infections was inadequate in
this study. Irrigation and debridement best
serves as an adjunctive rather than a primary
therapy [6,28].
In situ graft replacement supplemented
with muscle flaps is a promising strategy for
complicated perigraft infections that may
not tolerate extra anatomic reconstruction.
Preserving the vascularization route with in
situ graft replacement and reinforcing it with
muscle flaps increases limb salvage options
for Samson group 4 and group 5 infections.
However, we were unable to demonstrate
statistical significance with in situ graft re-
placement and muscle flap transposition in
Samson groups 4 and 5 because of our small
sample size and the infrequent use of this
therapy. Graft salvage likely has limited ap-
plication in Samson group 5 patients —
those with sepsis, graft occlusion, and anas-
tomotic hemorrhage. The current literature
suggests excision of the graft is generally in-
dicated and should be performed if tolerated
[8,28].
Incorporating the information gathered
regarding graft salvage for given grade of in-
fection with bacteriology data has allowed a
logical management algorithm to be estab-
lished for the treatment of extracavitary
prosthetic vascular graft infections [28]. Our
study critically evaluated how this knowl-
edge is incorporated into surgical manage-
ment of prosthetic vascular graft infections
from three institutions in the United States.
This study supports a surgical strategy
for extracavitary vascular graft infections
basedprimarilyonthedegreeofinfectionand
microbiology. Vascular graft infections
shouldberegardedasdynamicprocessesthat
changeasquicklyastheorganismsthatcreate
them. This challenging clinical problem re-
quiresperiodicreviewthatwillleadtosignif-
icant changes in management algorithm in
the future. Other factors, such as patient vas-
cular anatomy and implant location, are also
essential to determine the optimal method of
limbsalvage.Ifallthesecriteriaareexamined
beforetherapy,standardizationisfeasibleand
successful outcomes will become more pre-
dictable and routine even in the face of this
rapidly evolving pathological process.
There were several limitations in this
study. Surgeons selected which procedures
119 Narayan: Prosthetic vascular graft infectionwouldbeperformedoneachpatientinanon-
randomized manner. The surgeon’s past ex-
perience and comfort level will often
determine choice of procedure. The clinical
assessment of severity of infection may also
differ among surgeons, and this was con-
trolled for by the use of a unified grading
system. Another factor that may influence
the choice of intervention is the presence of
a working relationship between the vascular
surgeon and a plastic surgeon. Not all vascu-
lar surgeons have a strong relationship with
a plastic surgeon, whereby they may not opt
for vascular graft salvage using muscle flaps
when indicated. The study will be strength-
ened if it can be repeated in a prospective
fashion, with greater than three institutions
involved, and a larger sample size.
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